• Liraglutide  CAS 204656-20-2 vail Lyophilized Peptide
  • Liraglutide  CAS 204656-20-2 vail Lyophilized Peptide
  • Liraglutide  CAS 204656-20-2 vail Lyophilized Peptide
  • Liraglutide  CAS 204656-20-2 vail Lyophilized Peptide
  • Liraglutide  CAS 204656-20-2 vail Lyophilized Peptide
  • Liraglutide  CAS 204656-20-2 vail Lyophilized Peptide
  • Liraglutide  CAS 204656-20-2 vail Lyophilized Peptide
  • Liraglutide  CAS 204656-20-2 vail Lyophilized Peptide
  • Liraglutide  CAS 204656-20-2 vail Lyophilized Peptide
  • Liraglutide  CAS 204656-20-2 vail Lyophilized Peptide
  • Liraglutide  CAS 204656-20-2 vail Lyophilized Peptide
  • Liraglutide  CAS 204656-20-2 vail Lyophilized Peptide
  • Liraglutide  CAS 204656-20-2 vail Lyophilized Peptide
  • Liraglutide  CAS 204656-20-2 vail Lyophilized Peptide
  • Liraglutide  CAS 204656-20-2 vail Lyophilized Peptide
  • Liraglutide  CAS 204656-20-2 vail Lyophilized Peptide
  • Liraglutide  CAS 204656-20-2 vail Lyophilized Peptide
  • Liraglutide  CAS 204656-20-2 vail Lyophilized Peptide

Liraglutide CAS 204656-20-2 vail Lyophilized Peptide

No.204656-20-2
Product Name: Liraglutide 
CAS:  204656-20-2
CBNumber: CB31179049
Molecular Formula: C172H265N43O51
Specification: 2mg,5mg,10mg
Specification:
2mg
5mg
10mg
  • Liraglutide  CAS 204656-20-2 vail Lyophilized Peptide
  • Liraglutide  CAS 204656-20-2 vail Lyophilized Peptide
  • Liraglutide  CAS 204656-20-2 vail Lyophilized Peptide
  • Liraglutide  CAS 204656-20-2 vail Lyophilized Peptide
  • Liraglutide  CAS 204656-20-2 vail Lyophilized Peptide
  • Liraglutide  CAS 204656-20-2 vail Lyophilized Peptide
  • Liraglutide  CAS 204656-20-2 vail Lyophilized Peptide
  • Liraglutide  CAS 204656-20-2 vail Lyophilized Peptide
  • Liraglutide  CAS 204656-20-2 vail Lyophilized Peptide

Description

Liraglutide is a GLP-1 analog used in the management of type 2 diabetes mellitus, prevention of cardiovascular complications associated with diabetes, and obesity.

Liraglutide is a once-daily GLP-1 derivative for the treatment of type 2 diabetesLabel,2. The prolonged action of liraglutide is achieved by attaching a fatty acid molecule at position 26 of the GLP-1 molecule, enabling it to bind reversibly to albumin within the subcutaneous tissue and bloodstream and be released slowly over timeLabel,2,3. Binding with albumin results in slower degradation and reduced elimination of liraglutide from the circulation by the kidneys compared to GLP-12,3. The effect of liraglutide is the increased secretion of insulin and decreased secretion of glucagon in response to glucose as well as slower gastric emptyingLabel. Liraglutide also does not adversely affect glucagon secretion in response to low blood sugarLabel,2. 

Specifications

Aliase  liraglutide
CAS 204656-20-2
EINECS 1592732-453-0
MOLECULAR FORMULA C172H265N43O51
MOLECULAR WEIGHT 3751.20000
Purity 99%
Our Service Advantages

Packaging and Delivery
The company fully supports customized packing and shipping preferences to meet specific needs, ensuring top priority for customer requirements.

Supply Ability
The MOQ varies by product due to their unique specifications. We encourage you to reach out for detailed information tailored to the specific product of interest.

Lead Time
Delivery schedules adapt to seasonal demands, with a 15 working day delivery time during peak seasons and 7 to 13 working days in off-peak seasons, showcasing efficient and timely delivery.